| pathology | Demonstrated benefit and harm | k | | | |
|---|
| acute coronary syndrome | versus placebo or control No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Prandoni, 1991 | aspirin + dipyridamol vs placebo | | | Vasc events 0,55 [0,22; 1,35] Major bleeds NaN [NaN; NaN] Vasc deaths ∞ [NaN; ∞] Non-fatal stroke NaN [NaN; NaN] Non-fatal MI 0,45 [0,17; 1,20] Non vasc deaths ∞ [NaN; ∞] cardiovascular events 0,55 [0,22; 1,35] |
| Trial | Treatments | Patients | Method |
|---|
| Prandoni, 1991 | Aspirin 50mg/d + Dipyridamol 400mg/d (n=44) vs. placebo (n=44) | patients with acute unstable angina | double blind Sample size: 44/44 Primary endpoint: FU duration: 12m |
|
| CABG surgery | versus No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| GESIC (aspirin+dipyridamol), 1990 | aspirin + dipyridamol vs placebo | | | vascular death 1,81 [0,61; 5,36] vascular event 1,81 [0,61; 5,36] |
| Trial | Treatments | Patients | Method |
|---|
| GESIC (aspirin+dipyridamol), 1990 | aspirin 50 mg + dipyridamole 75mg 3 times daily
(n=368) vs. placebo
(n=371) 3 arms trials: placebo, aspirin, aspirin + dipyridamole
| patients undergoing CABG
| double blind Parallel groups Sample size: 368/371 Primary endpoint: FU duration: 28d
|
|
| CABG surgery | versus placebo or control No demonstrated result for efficacy | 12 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Brooks, 1985 | aspirin + dipyridamol vs placebo | | | vascular death 2,00 [0,61; 6,51] non vascular death NaN [NaN; NaN] vascular event 2,00 [0,61; 6,51] | | Mayo-A, 1984 | aspirin + dipyridamol vs placebo | | | vascular death 0,85 [0,26; 2,73] vascular event 0,85 [0,26; 2,73] | | Pantely, 1979 | aspirin + dipyridamol vs control | | | vascular death NaN [NaN; NaN] Non fatal stroke NaN [NaN; NaN] non fatal MI NaN [NaN; NaN] non vascular death NaN [NaN; NaN] vascular event NaN [NaN; NaN] | | Wadsworth, 1985 | aspirin + dipyridamol vs placebo | | | vascular death 2,13 [0,20; 23,06] Non fatal stroke 1,06 [0,07; 16,75] non vascular death NaN [NaN; NaN] vascular event 1,59 [0,27; 9,33] | | Brussels, 1987 | aspirin + dipyridamol vs control | | | vascular death ∞ [NaN; ∞] Non fatal stroke 0,00 [0,00; NaN] non fatal MI 0,52 [0,05; 5,38] non vascular death NaN [NaN; NaN] vascular event 0,69 [0,13; 3,80] | | Basel, 1989 | aspirin + dipyridamol vs placebo | | | vascular death NaN [NaN; NaN] non fatal MI 0,00 [0,00; NaN] non vascular death NaN [NaN; NaN] vascular event 0,00 [0,00; NaN] | | aspirin + dipyridamol vs placebo | | | | | aspirin + dipyridamol vs control | | | | | aspirin + dipyridamol vs placebo | | | | | aspirin + dipyridamol vs control | | | | | dipyridamol vs control | | | | | dipyridamol vs placebo | | | |
| Trial | Treatments | Patients | Method |
|---|
| Brooks, 1985 | aspirin 990 mg and dipyridamole 225 mg daily (n=160) vs. placebo (n=160) | patients undergoing coronary bypass grafting | double blind Sample size: 160/160 Primary endpoint: FU duration: 12m | | Mayo-A, 1984 | aspirin 975 + dipiridamol 225 (n=202) vs. placebo (n=205) | patients undergoing coronary bypass grafting | double blind Sample size: 202/205 Primary endpoint: FU duration: 12m | | Pantely, 1979 | aspirin 325 mg three times a day + dipyridamole 75 mg three times a day (n=18) vs. control (n=30) | patients undergoing aortocoronary saphenous-vein bypass-graft surgery | open Sample size: 18/30 Primary endpoint: FU duration: 6m | | Wadsworth, 1985 | aspirin 975 mg/d + dipiridamol 225 mg/d, aspirin 975 mg/d (n=96) vs. placebo (n=102) | coronary bypass patients | double blind Sample size: 96/102 Primary endpoint: FU duration: 12m | | Brussels, 1987 | aspirin 200 + dipiridamol 400 (H) (n=24) vs. (n=25) | | Sample size: 24/25 Primary endpoint: FU duration: 12m | | Basel, 1989 | aspirin 50 + dipiridamol 400 (n=62) vs. placebo (n=63) | patients who had aortocoronary vein bypass surgery | double blind Sample size: 62/63 Primary endpoint: FU duration: 9m | | Leeds-B, 1985 | aspirin 990 + dipiridamol 225 (W) (n=61) vs. placebo (n=64) | patients undergoing aorta-coronary bypass grafting for disabling angina | double blind Sample size: 61/64 Primary endpoint: FU duration: 6m | | Czech, 1986 | aspirin 1000 + dipiridamol 225 (n=47) vs. control (no medication) (n=46) | Patients with aortocoronary bypasses with intraoperative blood flow rates of 40 ml/min or less | open Sample size: 47/46 Primary endpoint: FU duration: 12m | | Thaulow, 1987 | aspirin 975 + dipiridamol 225 (n=34) vs. placebo (n=35) | Patients scheduled to receive at least three aortocoronary venous bypass grafts | double blind Sample size: 34/35 Primary endpoint: FU duration: 3m | | Des Moines, 1980 | aspirin 20 + dipiridamol 100 (n=60) vs. (n=54) | | Sample size: 60/54 Primary endpoint: FU duration: 12m | | Toronto dipyridamole, 1987 | dipiridamol 400 (n=20) vs. control (n=20) | patients undergoing elective coronary artery bypass grafting | Sample size: 20/20 Primary endpoint: FU duration: 48h | | Ekestrom, 1990 | dipiridamol 100 mg orally q.i.d. (n=174) vs. placebo (n=186) | patients undergoing coronary bypass surgery | double blind Sample size: 174/186 Primary endpoint: FU duration: 12m |
|
| cardiovascular prevention | versus placebo or control No demonstrated result for efficacy | 15 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| PARIS, 1980 | dipyridamol + aspirin vs placebo | | | Stroke 0,63 [0,25; 1,58] | | PARIS-II, 1986 | dipyridamol + aspirin vs placebo | | | Stroke 0,61 [0,35; 1,05] | | aspirin + dipyridamol vs placebo | | | | | aspirin + dipyridamol vs placebo | | | | | aspirin + dipyridamol vs placebo | | | | | Atlanta (Sbar), 1967 | dipyridamol vs control | | | vascular death ∞ [NaN; ∞] Non fatal stroke ∞ [NaN; ∞] Non fatal MI 0,75 [0,18; 3,07] non vascular death NaN [NaN; NaN] vascular event 1,25 [0,37; 4,21] | | Becker, 1967 | dipyridamol vs control | | | vascular death ∞ [NaN; ∞] Non fatal stroke NaN [NaN; NaN] Non fatal MI NaN [NaN; NaN] non vascular death NaN [NaN; NaN] vascular event ∞ [NaN; ∞] | | Wirecki, 1967 | dipyridamol vs control | | | vascular death NaN [NaN; NaN] Non fatal stroke NaN [NaN; NaN] Non fatal MI NaN [NaN; NaN] non vascular death NaN [NaN; NaN] vascular event NaN [NaN; NaN] | | dipyridamol vs placebo | | | | | dipyridamol vs placebo | | | | | dipyridamol vs placebo | | | | | dipyridamol vs placebo | | | | | dipyridamol vs placebo | | | | | dipyridamol vs placebo | | | | | dipyridamol vs placebo | | | |
| Trial | Treatments | Patients | Method |
|---|
| PARIS, 1980 | Aspirin (324 mg) + dipyridamole (75 mg) 3x/d (n=810) vs. Placebo (n=406) | patients who had recovered from myocardial infarction | Double blind Parallel groups Sample size: 810/406 Primary endpoint: No primary outcome clearly defined FU duration: 41 months (mean) part of 3-group trial | | PARIS-II, 1986 | Aspirin (330 mg) + dipyridamole (75 mg) 3x/d (n=1563) vs. Placebo (n=1565) | patients who had recovered from myocardial infarction, suffered from 4 weeks to 4 months previously | Double blind Parallel groups Sample size: 1563/1565 Primary endpoint: No primary outcome clearly defined FU duration: 23.4 months | | Hess (2), 1985 | Aspirine Dipyridamole 330 mg / j 225 mg / j (n=80) vs. Placebo (n=80) | patients with occlusive arterial disease in the lower extremities | double blind Parallel groups Sample size: 80/80 Primary endpoint: Score de progression de l’athérosclérose FU duration: | | Schoop (2), 1983 | Aspirine Dipyridamole 990 mg / j 225 mg /j (n=100) vs. Placebo (n=100) | AOMI stade non précisé | double blind Parallel groups Sample size: 100/100 Primary endpoint: Progression de l’athérosclérose FU duration: | | VA study, 1986 | Aspirine + Dipyridamole 975 mg / j 225 mg /j (n=110) vs. Placebo (n=121) | non-insulin-dependent diabetic men with either a recent amputation for gangrene or active gangrene | double blind Parallel groups Sample size: 110/121 Primary endpoint: Mortalité due à une pathologie vasculaire athérosclérotique ou amputation pour gangrène au membre op FU duration: 46 months | | Atlanta (Sbar), 1967 | dipyridamole 150mg daily (n=30) vs. placebo (n=30) | patients with angina pectoris | double-blind parallel groups Sample size: 30/30 Primary endpoint: not defined FU duration: 6 months | | Becker, 1967 | dipyridamole 225mg daily (n=14) vs. placebo (n=13) | | double-blind parallel groups Sample size: 14/13 Primary endpoint: not defined FU duration: 5 months | | Wirecki, 1967 | dipyridamole 150mg daily (n=28) vs. placebo (n=28) | patients with angina pectoris | double blind parallel groups Sample size: 28/28 Primary endpoint: not defined FU duration: 7 months | | Igloe, 1970 | Dipyridamole 200mg daily (n=26) vs. placebo (n=22) | patients with angina pectoris | double blind parallel groups Sample size: 26/22 Primary endpoint: not defined FU duration: 2-7 months | | Zion, 1961 | Dipyridamole 37.5mg (n=14) vs. placebo (n=14) | patients with angina pectoris | double-blind cross-over Sample size: 14/14 Primary endpoint: not defined FU duration: 0.5 months | | Kinsella, 1962 | dipyridamole 37.5 mg and 100mg daily (n=13) vs. placebo (n=13) | | double-blind parallel groups Sample size: 13/13 Primary endpoint: not defined FU duration: 0.5 months | | Leiberman, 1964 | dipyridamole 100mg daily (n=19) vs. placebo (n=19) | | double blind parallel groups Sample size: 19/19 Primary endpoint: not defined FU duration: >3 months | | Dewar, 1961 | Dipyridamole 100mg daily (n=17) vs. placebo (n=17) | patients with angina pectoris | double-blind parallel groups Sample size: 17/17 Primary endpoint: not defined FU duration: 0.5 months | | Neumann, 1964 | dipyridamole 150mg daily (n=20) vs. placebo (n=16) | elderly with precordial pain | double-blind parallel groups Sample size: 20/16 Primary endpoint: not defined FU duration: 1.5 months | | Foulds, 1960 | Dipyridamole 200mg daily (n=24) vs. placebo (n=24) | patients with angina pectoris | double-blind parallel groups Sample size: 24/24 Primary endpoint: not defined FU duration: 1 months |
|
| cardiovascular prevention | versus aspirin No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| PARIS, 1980 | dipyridamol + aspirin vs aspirin | | | Death or nonfatal MI 1,05 [0,84; 1,30] |
| Trial | Treatments | Patients | Method |
|---|
| PARIS, 1980 | Aspirin (324 mg) + dipyridamole (75 mg) 3x/d (n=810) vs. Aspirin (324 mg) 3x/d (n=810) | patuents who had recovered from myocardial infarction | Double blind Parallel groups Sample size: 810/810 Primary endpoint: No primary outcome clearly defined FU duration: 41 months part of 3-group trial |
|
| coronary artery disease | versus placebo or control No demonstrated result for efficacy | 12 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| PARIS, 1980 | dipyridamol + aspirin vs placebo | | | Stroke 0,63 [0,25; 1,58] | | PARIS-II, 1986 | dipyridamol + aspirin vs placebo | | | Stroke 0,61 [0,35; 1,05] | | Atlanta (Sbar), 1967 | dipyridamol vs control | | | vascular death ∞ [NaN; ∞] Non fatal stroke ∞ [NaN; ∞] Non fatal MI 0,75 [0,18; 3,07] non vascular death NaN [NaN; NaN] vascular event 1,25 [0,37; 4,21] | | Becker, 1967 | dipyridamol vs control | | | vascular death ∞ [NaN; ∞] Non fatal stroke NaN [NaN; NaN] Non fatal MI NaN [NaN; NaN] non vascular death NaN [NaN; NaN] vascular event ∞ [NaN; ∞] | | Wirecki, 1967 | dipyridamol vs control | | | vascular death NaN [NaN; NaN] Non fatal stroke NaN [NaN; NaN] Non fatal MI NaN [NaN; NaN] non vascular death NaN [NaN; NaN] vascular event NaN [NaN; NaN] | | dipyridamol vs placebo | | | | | dipyridamol vs placebo | | | | | dipyridamol vs placebo | | | | | dipyridamol vs placebo | | | | | dipyridamol vs placebo | | | | | dipyridamol vs placebo | | | | | dipyridamol vs placebo | | | |
| Trial | Treatments | Patients | Method |
|---|
| PARIS, 1980 | Aspirin (324 mg) + dipyridamole (75 mg) 3x/d (n=810) vs. Placebo (n=406) | patients who had recovered from myocardial infarction | Double blind Parallel groups Sample size: 810/406 Primary endpoint: No primary outcome clearly defined FU duration: 41 months (mean) part of 3-group trial | | PARIS-II, 1986 | Aspirin (330 mg) + dipyridamole (75 mg) 3x/d (n=1563) vs. Placebo (n=1565) | patients who had recovered from myocardial infarction, suffered from 4 weeks to 4 months previously | Double blind Parallel groups Sample size: 1563/1565 Primary endpoint: No primary outcome clearly defined FU duration: 23.4 months | | Atlanta (Sbar), 1967 | dipyridamole 150mg daily (n=30) vs. placebo (n=30) | patients with angina pectoris | double-blind parallel groups Sample size: 30/30 Primary endpoint: not defined FU duration: 6 months | | Becker, 1967 | dipyridamole 225mg daily (n=14) vs. placebo (n=13) | | double-blind parallel groups Sample size: 14/13 Primary endpoint: not defined FU duration: 5 months | | Wirecki, 1967 | dipyridamole 150mg daily (n=28) vs. placebo (n=28) | patients with angina pectoris | double blind parallel groups Sample size: 28/28 Primary endpoint: not defined FU duration: 7 months | | Igloe, 1970 | Dipyridamole 200mg daily (n=26) vs. placebo (n=22) | patients with angina pectoris | double blind parallel groups Sample size: 26/22 Primary endpoint: not defined FU duration: 2-7 months | | Zion, 1961 | Dipyridamole 37.5mg (n=14) vs. placebo (n=14) | patients with angina pectoris | double-blind cross-over Sample size: 14/14 Primary endpoint: not defined FU duration: 0.5 months | | Kinsella, 1962 | dipyridamole 37.5 mg and 100mg daily (n=13) vs. placebo (n=13) | | double-blind parallel groups Sample size: 13/13 Primary endpoint: not defined FU duration: 0.5 months | | Leiberman, 1964 | dipyridamole 100mg daily (n=19) vs. placebo (n=19) | | double blind parallel groups Sample size: 19/19 Primary endpoint: not defined FU duration: >3 months | | Dewar, 1961 | Dipyridamole 100mg daily (n=17) vs. placebo (n=17) | patients with angina pectoris | double-blind parallel groups Sample size: 17/17 Primary endpoint: not defined FU duration: 0.5 months | | Neumann, 1964 | dipyridamole 150mg daily (n=20) vs. placebo (n=16) | elderly with precordial pain | double-blind parallel groups Sample size: 20/16 Primary endpoint: not defined FU duration: 1.5 months | | Foulds, 1960 | Dipyridamole 200mg daily (n=24) vs. placebo (n=24) | patients with angina pectoris | double-blind parallel groups Sample size: 24/24 Primary endpoint: not defined FU duration: 1 months |
|
| coronary artery disease | versus aspirin No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| PARIS, 1980 | dipyridamol + aspirin vs aspirin | | | Death or nonfatal MI 1,05 [0,84; 1,30] |
| Trial | Treatments | Patients | Method |
|---|
| PARIS, 1980 | Aspirin (324 mg) + dipyridamole (75 mg) 3x/d (n=810) vs. Aspirin (324 mg) 3x/d (n=810) | patuents who had recovered from myocardial infarction | Double blind Parallel groups Sample size: 810/810 Primary endpoint: No primary outcome clearly defined FU duration: 41 months part of 3-group trial |
|
| percutaneous coronary intervention | versus placebo or control No demonstrated result for efficacy | 4 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Schwartz (Toronto), 1988 | aspirin + dipyridamol vs placebo | Non fatal MI 0,28 [0,13; 0,64] Non fatal MI 0,28 [0,13; 0,64] vascular events 0,28 [0,13; 0,64] | | vascular deaths NaN [NaN; NaN] Non fatal stroke NaN [NaN; NaN] non vascular death NaN [NaN; NaN] | | White (aspirin+dipiridamol), 1991 | aspirin + dipyridamol vs placebo | | | Non fatal MI 1,45 [0,66; 3,21] vascular deaths 2,07 [0,19; 22,72] Non fatal stroke 0,00 [0,00; NaN] Non fatal MI 1,45 [0,66; 3,21] vascular events 1,38 [0,67; 2,86] non vascular death NaN [NaN; NaN] | | Nye (Dunedin), 1990 | aspirin + dipyridamol vs placebo | | | Non fatal MI NaN [NaN; NaN] vascular deaths NaN [NaN; NaN] Non fatal stroke NaN [NaN; NaN] Non fatal MI NaN [NaN; NaN] vascular events NaN [NaN; NaN] non vascular death NaN [NaN; NaN] | | Mayo-PTCA, 1989 | aspirin + dipyridamol vs placebo | | | Non fatal MI 1,54 [0,26; 9,05] vascular deaths NaN [NaN; NaN] Non fatal MI 1,54 [0,26; 9,05] vascular events 1,54 [0,26; 9,05] non vascular death NaN [NaN; NaN] |
| Trial | Treatments | Patients | Method |
|---|
| Schwartz (Toronto), 1988 | aspirin 990 + D225 (H) (n=187) vs. placebo (n=189) | | double blind Parallel groups Sample size: 187/189 Primary endpoint: FU duration: 6m | | White (aspirin+dipiridamol), 1991 | ticlopidine 500, aspirin 650 + D225 (n=245) vs. (n=254) | | Parallel groups Sample size: 245/254 Primary endpoint: FU duration: 6m | | Nye (Dunedin), 1990 | aspirin 300 + D225 (n=35) vs. placebo (n=37) | | NA Parallel groups Sample size: 35/37 Primary endpoint: FU duration: 12m | | Mayo-PTCA, 1989 | aspirin 975 + D225 (n=102) vs. (n=105) | | Parallel groups Sample size: 102/105 Primary endpoint: FU duration: 48h |
|
| peripheral vascular diseases | versus placebo or control No demonstrated result for efficacy | 3 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| aspirin + dipyridamol vs placebo | | | | | aspirin + dipyridamol vs placebo | | | | | aspirin + dipyridamol vs placebo | | | |
| Trial | Treatments | Patients | Method |
|---|
| Hess (2), 1985 | Aspirine Dipyridamole 330 mg / j 225 mg / j (n=80) vs. Placebo (n=80) | patients with occlusive arterial disease in the lower extremities | double blind Parallel groups Sample size: 80/80 Primary endpoint: Score de progression de l’athérosclérose FU duration: | | Schoop (2), 1983 | Aspirine Dipyridamole 990 mg / j 225 mg /j (n=100) vs. Placebo (n=100) | AOMI stade non précisé | double blind Parallel groups Sample size: 100/100 Primary endpoint: Progression de l’athérosclérose FU duration: | | VA study, 1986 | Aspirine + Dipyridamole 975 mg / j 225 mg /j (n=110) vs. Placebo (n=121) | non-insulin-dependent diabetic men with either a recent amputation for gangrene or active gangrene | double blind Parallel groups Sample size: 110/121 Primary endpoint: Mortalité due à une pathologie vasculaire athérosclérotique ou amputation pour gangrène au membre op FU duration: 46 months |
|
| post myocardial infarction | versus placebo or control No demonstrated result for efficacy | 2 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| PARIS, 1980 | dipyridamol + aspirin vs placebo | | | Stroke 0,63 [0,25; 1,58] | | PARIS-II, 1986 | dipyridamol + aspirin vs placebo | | | Stroke 0,61 [0,35; 1,05] |
| Trial | Treatments | Patients | Method |
|---|
| PARIS, 1980 | Aspirin (324 mg) + dipyridamole (75 mg) 3x/d (n=810) vs. Placebo (n=406) | patients who had recovered from myocardial infarction | Double blind Parallel groups Sample size: 810/406 Primary endpoint: No primary outcome clearly defined FU duration: 41 months (mean) part of 3-group trial | | PARIS-II, 1986 | Aspirin (330 mg) + dipyridamole (75 mg) 3x/d (n=1563) vs. Placebo (n=1565) | patients who had recovered from myocardial infarction, suffered from 4 weeks to 4 months previously | Double blind Parallel groups Sample size: 1563/1565 Primary endpoint: No primary outcome clearly defined FU duration: 23.4 months |
|
| post myocardial infarction | versus aspirin No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| PARIS, 1980 | dipyridamol + aspirin vs aspirin | | | Death or nonfatal MI 1,05 [0,84; 1,30] |
| Trial | Treatments | Patients | Method |
|---|
| PARIS, 1980 | Aspirin (324 mg) + dipyridamole (75 mg) 3x/d (n=810) vs. Aspirin (324 mg) 3x/d (n=810) | patuents who had recovered from myocardial infarction | Double blind Parallel groups Sample size: 810/810 Primary endpoint: No primary outcome clearly defined FU duration: 41 months part of 3-group trial |
|
| stable angina | versus placebo or control No demonstrated result for efficacy | 10 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Atlanta (Sbar), 1967 | dipyridamol vs control | | | vascular death ∞ [NaN; ∞] Non fatal stroke ∞ [NaN; ∞] Non fatal MI 0,75 [0,18; 3,07] non vascular death NaN [NaN; NaN] vascular event 1,25 [0,37; 4,21] | | Becker, 1967 | dipyridamol vs control | | | vascular death ∞ [NaN; ∞] Non fatal stroke NaN [NaN; NaN] Non fatal MI NaN [NaN; NaN] non vascular death NaN [NaN; NaN] vascular event ∞ [NaN; ∞] | | Wirecki, 1967 | dipyridamol vs control | | | vascular death NaN [NaN; NaN] Non fatal stroke NaN [NaN; NaN] Non fatal MI NaN [NaN; NaN] non vascular death NaN [NaN; NaN] vascular event NaN [NaN; NaN] | | dipyridamol vs placebo | | | | | dipyridamol vs placebo | | | | | dipyridamol vs placebo | | | | | dipyridamol vs placebo | | | | | dipyridamol vs placebo | | | | | dipyridamol vs placebo | | | | | dipyridamol vs placebo | | | |
| Trial | Treatments | Patients | Method |
|---|
| Atlanta (Sbar), 1967 | dipyridamole 150mg daily (n=30) vs. placebo (n=30) | patients with angina pectoris | double-blind parallel groups Sample size: 30/30 Primary endpoint: not defined FU duration: 6 months | | Becker, 1967 | dipyridamole 225mg daily (n=14) vs. placebo (n=13) | | double-blind parallel groups Sample size: 14/13 Primary endpoint: not defined FU duration: 5 months | | Wirecki, 1967 | dipyridamole 150mg daily (n=28) vs. placebo (n=28) | patients with angina pectoris | double blind parallel groups Sample size: 28/28 Primary endpoint: not defined FU duration: 7 months | | Igloe, 1970 | Dipyridamole 200mg daily (n=26) vs. placebo (n=22) | patients with angina pectoris | double blind parallel groups Sample size: 26/22 Primary endpoint: not defined FU duration: 2-7 months | | Zion, 1961 | Dipyridamole 37.5mg (n=14) vs. placebo (n=14) | patients with angina pectoris | double-blind cross-over Sample size: 14/14 Primary endpoint: not defined FU duration: 0.5 months | | Kinsella, 1962 | dipyridamole 37.5 mg and 100mg daily (n=13) vs. placebo (n=13) | | double-blind parallel groups Sample size: 13/13 Primary endpoint: not defined FU duration: 0.5 months | | Leiberman, 1964 | dipyridamole 100mg daily (n=19) vs. placebo (n=19) | | double blind parallel groups Sample size: 19/19 Primary endpoint: not defined FU duration: >3 months | | Dewar, 1961 | Dipyridamole 100mg daily (n=17) vs. placebo (n=17) | patients with angina pectoris | double-blind parallel groups Sample size: 17/17 Primary endpoint: not defined FU duration: 0.5 months | | Neumann, 1964 | dipyridamole 150mg daily (n=20) vs. placebo (n=16) | elderly with precordial pain | double-blind parallel groups Sample size: 20/16 Primary endpoint: not defined FU duration: 1.5 months | | Foulds, 1960 | Dipyridamole 200mg daily (n=24) vs. placebo (n=24) | patients with angina pectoris | double-blind parallel groups Sample size: 24/24 Primary endpoint: not defined FU duration: 1 months |
|
| thrombosis prevention | versus No demonstrated result for efficacy | 2 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Chicago, 1982 | aspirin + dipyridamol vs control | | | Deep venous thrombosis 0,63 [0,20; 1,99] non fatal pulmonary embolism NaN [NaN; NaN] Fatal pulmonary embolism NaN [NaN; NaN] non pulmonary embolism death NaN [NaN; NaN] | | Frankfurt, 1981 | aspirin + dipyridamol vs placebo | | | major bleeding NaN [NaN; NaN] Deep venous thrombosis 2,00 [0,15; 26,19] non fatal pulmonary embolism NaN [NaN; NaN] Fatal pulmonary embolism 0,00 [0,00; NaN] non pulmonary embolism death ∞ [NaN; ∞] |
| Trial | Treatments | Patients | Method |
|---|
| Chicago, 1982 | aspirin, 300 mg bid, and dipyridamole, 75 mg tid (n=12) vs. control (n=15) | patients with acute spinal cord injury | open Parallel groups Sample size: 12/15 Primary endpoint: FU duration: | | Frankfurt, 1981 | A+Dip,A1320 (n=25) vs. placebo (n=14) | patients with myocardial infarction | double-blind Parallel groups Sample size: 25/14 Primary endpoint: FU duration: |
|
| thrombosis prevention | versus placebo or control No demonstrated result for efficacy | 10 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Parodi I, 1973 | dipyridamol + aspirin vs control | Deep venous thrombosis 0,37 [0,15; 0,90] | | non fatal pulmonary embolism NaN [NaN; NaN] Fatal pulmonary embolism NaN [NaN; NaN] non pulmonary embolism death NaN [NaN; NaN] | | dipyridamol + aspirin vs control | | | | | dipyridamol + aspirin vs control | | | | | dipyridamol + aspirin vs control | | | | | dipyridamol + aspirin vs control | | | | | dipyridamol + aspirin vs placebo | | | | | dipyridamol + aspirin vs placebo | | | | | dipyridamol + aspirin vs control | | | | | dipyridamol + aspirin vs control | | | | | dipyridamol + aspirin vs control | | | |
| Trial | Treatments | Patients | Method |
|---|
| Parodi I, 1973 | Dip,A1000+Dip (n=40) vs. control (n=22) | | open Sample size: 40/22 Primary endpoint: FU duration: | | Parodi II, 1973 | A1500,Dip,A+Dip (n=91) vs. control (n=35) | | open Sample size: 91/35 Primary endpoint: FU duration: | | Zekert-III, 1977 | A1500,A1300+Dip,A1000+Dip (n=135) vs. control (n=46) | | open Sample size: 135/46 Primary endpoint: FU duration: | | Australian I, 1975 | A1000+Dip (n=75) vs. control (n=75) | | open Sample size: 75/75 Primary endpoint: FU duration: | | Australian II, 1976 | A1000+Dip (n=85) vs. control (n=75) | | open Sample size: 85/75 Primary endpoint: FU duration: | | Encke IA, 1976 | A990,A+Dip (n=21) vs. Placebo (n=9) | | double-blind Sample size: 21/9 Primary endpoint: FU duration: | | Encke IB, 1976 | A1500,A990+Dip (n=62) vs. Placebo (n=34) | | double-blind Sample size: 62/34 Primary endpoint: FU duration: | | Toulouse I, 1979 | A990+Dip (n=38) vs. control (n=66) | | open Sample size: 38/66 Primary endpoint: FU duration: | | Harjola DVT, 1982 | A1500,Dip,A+Dip (n=300) vs. control (n=100) | | open Sample size: 300/100 Primary endpoint: FU duration: | | Weiss, 1977 | A990+Dip (n=30) vs. control (n=36) | | open Sample size: 30/36 Primary endpoint: FU duration: |
|
| thrombosis prevention | versus placebo or no treatment No demonstrated result for efficacy | 5 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Lyon-I, 1975 | aspirin + dipyridamol vs no treatment | DVT 0,13 [0,02; 0,91] | | non PE related death NaN [NaN; NaN] major bleeding NaN [NaN; NaN] non fatal PE NaN [NaN; NaN] fatal PE NaN [NaN; NaN] | | Hamburg, 1976 | aspirin + dipyridamol vs placebo | | | non PE related death NaN [NaN; NaN] major bleeding ∞ [NaN; ∞] DVT 0,39 [0,11; 1,45] non fatal PE NaN [NaN; NaN] fatal PE NaN [NaN; NaN] | | Morris-A , 1977 | dipyridamol vs no treatment | | | non PE related death NaN [NaN; NaN] major bleeding NaN [NaN; NaN] DVT 0,94 [0,62; 1,43] wound haematoma / infection NaN [NaN; NaN] fatal PE NaN [NaN; NaN] | | Morris-B , 1977 | aspirin + dipyridamol vs no treatment | | | non PE related death NaN [NaN; NaN] major bleeding NaN [NaN; NaN] DVT 0,95 [0,66; 1,38] non fatal PE NaN [NaN; NaN] wound haematoma / infection NaN [NaN; NaN] fatal PE NaN [NaN; NaN] | | Encke-II , 1976 | aspirin + dipyridamol vs placebo | | | non PE related death 1,47 [0,14; 15,33] major bleeding NaN [NaN; NaN] DVT 1,29 [0,64; 2,59] non fatal PE 0,74 [0,05; 11,20] fatal PE 0,00 [0,00; NaN] |
| Trial | Treatments | Patients | Method |
|---|
| Lyon-I, 1975 | Aspirin 1500 mg daily + Dipyridamole (n=20) vs. control (n=20) | Elective orthopaedic surgery | Sample size: 20/20 Primary endpoint: FU duration: 2 weeks | | Hamburg, 1976 | A+Dipyridamole,A1000 (n=21) vs. placebo (n=11) | Elective orthopaedic surgery | Sample size: 21/11 Primary endpoint: FU duration: 3 weeks | | Morris-A , 1977 | dipyridamole (n=24) vs. control (n=24) | elderly patients with hip fractures | open Parallel groups Sample size: 24/24 Primary endpoint: FU duration: | | Morris-B , 1977 | Aspirin 900 mg daily + dipyridamole (n=32) vs. control (n=32) | elderly patients with hip fractures | open Parallel groups Sample size: 32/32 Primary endpoint: FU duration: | | Encke-II , 1976 | Aspirin 1500mg daily, Aspirin 990mg daily + dipyridamol (n=34) vs. placebo (n=25) | patients with abdominal operations | double-blind Parallel groups Sample size: 34/25 Primary endpoint: FU duration: |
|
